Selank
Also Known As: TP-7, Selank peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro tuftsin analog, Anxiolytic peptide, Russian anti-anxiety peptide, Tuftsin analog, Anxioselective peptide, Nootropic peptide Selank, GABA-modulating peptide, Adaptogen peptide Selank, Selank nasal spray, anti-anxiety, nootropic, anxiolytic
Selank is a research-grade Synthetic heptapeptide anxiolytic / nootropic targeting Enkephalinase inhibition studied in Immunity & Wellness research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Research Compound - No approved human use; sold for laboratory research only.
A calming, nootropic peptide used in Russia for anxiety; Western evidence is thin.
At A Glance
| Category | Immunity & Wellness |
|---|---|
| Compound Class | Synthetic heptapeptide anxiolytic / nootropic; tuftsin analog (Thr-Lys-Pro-Arg-Pro-Gly-Pro) |
| Molecular Target | Enkephalinase inhibition; GABA-A receptor modulation; BDNF upregulation; serotonin/dopamine pathway; T-cell tuftsin receptor |
| Molecular Weight | 751.88 Da |
| Amino Acid Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| CAS Number | 129954-34-3 |
| Half-Life | ~2 minutes |
| WADA Status | not_listed |
| Evidence Tier | Research Compound |
Mechanism Of Action
It regulates the breakdown of natural calming chemicals in the brain (enkephalins) and boosts serotonin and dopamine, providing intense anxiety relief while actually improving cognitive focus.
Studied For
- Generalized anxiety disorder research
- Stress modulation
- Cognition / attention / focus
- Memory enhancement
- Anxiety reduction without sedation
- BDNF upregulation
- Serotonin system modulation
- Dopamine modulation
- GABAergic modulation
- Immune modulation via tuftsin analog
- Antidepressant research
- Alcohol withdrawal research
- ADHD research
- Nootropic research
- Neuroplasticity
- Adaptive stress response
- stress relief
- cognitive enhancement
- focus
- anxiety reduction
- depression
- immune modulation
- BDNF increase
Reported Research Findings
Russian studies report anxiolytic efficacy without sedation, dependence, or withdrawal. Largely single-lineage and preliminary; no large Western trials.
Safety And Handling Notes
Reported well tolerated; intranasal use may cause local nasal irritation.
Narrow, non-replicated evidence; registered as a medicine in Russia but not FDA or EMA approved. Research use only elsewhere.
Regulatory Status
Registered in Russia; not FDA or EMA approved.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.